Cargando…
Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiatio...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668547/ https://www.ncbi.nlm.nih.gov/pubmed/36404891 http://dx.doi.org/10.14309/crj.0000000000000905 |